RG
Rajkumar Ganesan
Amgen, Alector (United States), Stanford University School of Medicine, University of Zurich, Janssen Research and Development Spring House
0000-0002-3431-9664
Employment
-
Amgen Executive Director2022 - Present
-
Alector (United States) Head/Sr. Director2021 - 2022
-
Janssen Research and Development Spring House Director - Antibody Engineering/Bispecifics/CAR-T2017 - 2021
-
Boehringer Ingelheim Corp USA Senior Principal Scientist2012 - 2017
-
MedImmune LLC2010 - 2012
-
Genentech Inc2006 - 2010
Education
-
Stanford University School of Medicine2006 - 2006
-
University of Zurich PhD2002 - 2006
Projects & Funding
Projects & funding information is unavailable.
Publications (40)
- Data from Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform Save
- Data from Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform Save
- Supplementary Figures 1-3 from Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform Save
- Supplementary Figures 1-3 from Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform Save
- AbDiver: a tool to explore the natural antibody landscape to aid therapeutic design Save
- Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform Save
- A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway Save
- Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy Save
- High-Throughput Generation of Bipod (Fab × scFv) Bispecific Antibodies Exploits Differential Chain Expression and Affinity Capture. Save
- Discovery and characterization of single-domain antibodies for polymeric Ig receptor-mediated mucosal delivery of biologics Save